Thema: News: Microglia cyclooxygenase-2 activity in exp. gliomas
News: Microglia cyclooxygenase-2 activity in exp. gliomas
Dirk[a]
27.02.2003 15:33:48
Clin Cancer Res 2003 Feb;9(2):872-7 (Abstract)
Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation
Badie B, Schartner JM, Hagar AR, Prabakaran S, Peebles TR, Bartley B, Lapsiwala S, Resnick DK, Vorpahl J
Departments of Neurological Surgery [B. Bad., J. M. S., A. R. H., S. P., B. Bar., S. L., D. K. R., J. V.] and Radiology [T. R. P.], University of Wisconsin School of Medicine, Madison, Wisconsin 53792
PURPOSE:
Cerebral edema is responsible for significant morbidity and mortality in patients harboring malignant gliomas.
To examine the role of inflammatory cells in brain edema formation, we studied the expression cyclooxygenase (COX)-2, a key enzyme in arachidonic acid metabolism, by microglia in the C6 rodent glioma model.
EXPERIMENTAL DESIGN:
The expression of COX-2 in primary microglia cultures obtained from intracranial rat C6 gliomas was examined using reverse transcription-PCR, Western analysis, and prostaglandin E(2) (PGE(2)) enzyme immunoassay.
Blood-tumor barrier permeability was studied in the same tumor model using magnetic resonance imaging.
RESULTS:
In contrast to C6 glioma cells, microglia isolated from intracranial C6 tumors produced high levels of PGE(2) through a COX-2-dependent pathway. To test whether the observed microglia COX-2 activity played a role in brain edema formation in gliomas, tumor-bearing rats were treated with rofecoxib, a selective COX-2 inhibitor.
Rofecoxib was as effective as dexamethasone in decreasing the diffusion of contrast material into the brain parenchyma (P = 0.01, rofecoxib versus control animals), suggesting a reduction in blood-tumor barrier permeability.
CONCLUSIONS:
These findings suggest that glioma-infiltrating microglia are a major source of PGE(2) production through the COX-2 pathway and support the use of COX-2 inhibitors as possible alternatives to glucocorticoids in the treatment of peritumoral edema in patients with malignant brain tumors.
Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation
Badie B, Schartner JM, Hagar AR, Prabakaran S, Peebles TR, Bartley B, Lapsiwala S, Resnick DK, Vorpahl J
Departments of Neurological Surgery [B. Bad., J. M. S., A. R. H., S. P., B. Bar., S. L., D. K. R., J. V.] and Radiology [T. R. P.], University of Wisconsin School of Medicine, Madison, Wisconsin 53792
PURPOSE:
Cerebral edema is responsible for significant morbidity and mortality in patients harboring malignant gliomas.
To examine the role of inflammatory cells in brain edema formation, we studied the expression cyclooxygenase (COX)-2, a key enzyme in arachidonic acid metabolism, by microglia in the C6 rodent glioma model.
EXPERIMENTAL DESIGN:
The expression of COX-2 in primary microglia cultures obtained from intracranial rat C6 gliomas was examined using reverse transcription-PCR, Western analysis, and prostaglandin E(2) (PGE(2)) enzyme immunoassay.
Blood-tumor barrier permeability was studied in the same tumor model using magnetic resonance imaging.
RESULTS:
In contrast to C6 glioma cells, microglia isolated from intracranial C6 tumors produced high levels of PGE(2) through a COX-2-dependent pathway. To test whether the observed microglia COX-2 activity played a role in brain edema formation in gliomas, tumor-bearing rats were treated with rofecoxib, a selective COX-2 inhibitor.
Rofecoxib was as effective as dexamethasone in decreasing the diffusion of contrast material into the brain parenchyma (P = 0.01, rofecoxib versus control animals), suggesting a reduction in blood-tumor barrier permeability.
CONCLUSIONS:
These findings suggest that glioma-infiltrating microglia are a major source of PGE(2) production through the COX-2 pathway and support the use of COX-2 inhibitors as possible alternatives to glucocorticoids in the treatment of peritumoral edema in patients with malignant brain tumors.
Dirk[a]
